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THE COST-EFFECTIVENESS ANALYSIS OF 
LAMIVUDINE IN THE TREATMENT OF CHRONIC 
HEPATITIS B IN POLAND
Orlewska E
Unimed Research Centre for Pharmacoeconomics, Warsaw, 
Poland
OBJECTIVES: To estimate the C/E of lamivudine in the
treatment of chronic hepatitis B (CHB) in Poland.
METHODS: Model for the Polish health-care context
was developed, based on the use of clinical data from lit-
erature and local data on health-care resource utilisation
and unit cost. Costs and effects of a population of CHB
patients were modelled using 4 scenarios, which attempt
to reflect real-life practice, in which patients may receive
any of the treatment options available and a proportion
of patients may still receive no treatment because therapy
is not suitable. Scenario A and B assumed the availability
of both treatment options: the first choice of treatment is
in A-lamivudine and in B-INFa. In scenario C the only
approved treatment is INFa, in scenario D patient re-
ceived no antiviral treatment. The measure of outcomes
were: HBeAg seroconversion and nonprogression to cir-
rhosis. Only direct medical costs were analysed. The per-
spective of health-care payers and time horizon of 1 year
were taken. The one-way sensitivity analysis and extreme
scenario analysis were performed. RESULTS: The best
results in terms of seroconversion and nonprogression to
cirrhosis were achieved in scenario A, costs were lowest
in scenario D. Mean cost/HBeAg seroconvertion and
mean cost/cirrhosis avoided were (in PLN, 1 USD  4
PLN): for A—35238 and 6480, for B—72654 and
16289, for C—49370 and 8689, for D—20985 and
1474. The incremental analysis vs scenario D indicated,
that A is a more cost-effective alternative than B and C.
Changing in value of key drivers for sensitivity analysis
did not have any significant effect on the ICER. CON-
CLUSIONS: Lamivudine as the first choice treatment of
CHB (scenario A) allows to receive the best results in
terms of seroconversion and nonprogression to cirrhosis.
This is the most cost-effective alternative to “no treat-
ment” (scenario D).
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AN APPRAISAL OF HEALTH-RELATED QUALITY 
OF LIFE INSTRUMENTS FOR USE IN PATIENTS 
DIAGNOSED WITH HUMAN 
IMMUNODEFICIENCY VIRUS (HIV) DISEASE
Joshi AV, Nau DP, Kalsekar ID
West Virginia University, Morgantown, WV, USA
OBJECTIVES: The increasing effectiveness of medical
treatments for HIV (Human Immunodeficiency Virus)
has increased survival time of patients infected with the
virus. Because of the high incidence of side effects and the
burden of complex medication regimens, an increased
emphasis has been placed on the assessment of health-
related quality of life (HRQL) in HIV patients. The pur-
pose of this study is to review and compare instruments
used for measuring HRQL in HIV patients. METHODS:
Clinical trials involving HIV patients were identified
through the use of MEDLINE and AIDSLINE. The
HRQL instruments used in these trials included: 1) ge-
neric instruments such as the Medical Outcomes Study
(MOS) Short-Form (SF-36), Sickness Impact Profile, Not-
tingham Health Profile; 2) utility-based measures such as
the Quality of Well-Being Scale and the Q-TWIST (Qual-
ity adjusted Time Without Symptoms of disease and Tox-
icity); and 3) disease-specific instruments such as the
Multidimensional Quality of Life questionnaire for HIV
(MQoL-HIV), Functional Assessment of HIV Infection
(FAHI) scale, HIV/AIDS-Targeted Quality of Life Instru-
ment (HAT-QoL), HIV Overview of Problem/Evaluation
System (HOPES) instrument, HIV Patient Reported Sta-
tus and Experience (HIV-PARSE) scale, and the MOS-
HIV scale. Criteria for evaluating the instruments in-
cluded: comprehensiveness, respondent burden, internal
consistency of scales, test-retest reliability, clinical valid-
ity, and responsiveness to change. RESULTS: No instru-
ment was found to be completely devoid of ceiling ef-
fects. Although none of the instruments demonstrated
perfect psychometric properties, overall, the MOS-HIV
instrument fared better than all its counterparts. The in-
strument has minimal respondent burden and has shown
evidence of internal consistency, test-retest reliability, va-
lidity, and is responsive to changes over time. The instru-
ment has been widely used in clinical trials and has been
translated into 14 other languages, and translated forms
have been validated. CONCLUSIONS: The MOS-HIV
scale appears to be most optimal for HRQL measure-
ment in clinical trials involving HIV patients.
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PATTERNS OF ANTIBIOTIC USE AND COSTS 
ASSOCIATED WITH EPISODES OF TREATMENT 
FOR COMMON OUTPATIENT RESPIRATORY-
TRACT INFECTIONS: AN ANALYSIS OF 
MANAGED-CARE DATA
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Friedman M2, Hurley JS3, Harnett J4, Wilson J4
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OBJECTIVE: The objective of this study was to under-
stand the prescribing patterns and economic burden of
several common respiratory tract infections (RTIs) treated
in primary care. METHODS: Using eligibility and claims
data from the Lovelace Health Systems of Albuquerque,
New Mexico, we selected all outpatients treated with a
single antibiotic within 3 days of diagnosis between De-
cember 1997 and March 1999 for one of the following 4
RTIs: sinusitis, otitis media (OM), pharyngitis, and bron-
chitis. The patient’s index episode, the focus of this anal-
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ysis, was defined as the first infection identified following
a gap of at least 30 days in antibiotic use. The treatment
episode ended when there were no additional antibiotics
prescribed or infection-related outpatient medical visits
for 21 consecutive days. The costs of antibiotics, visits,
and tests were documented over the course of the epi-
sode. RESULTS: A total of 30,562 patients (11,798 with
sinusitis, 5,636 with otitis media, 7,310 with pharyngitis,
and 5,818 with bronchitis) met the study inclusion crite-
ria. For sinusitis, OM, and pharyngitis, penicillins were
the most widely prescribed antibiotics, followed by mac-
rolides, sulfonamides, cephalosporins, penicillin/B-lacta-
mase inhibitors, tetracyclines and fluroquinilones. Mac-
rolides were the most commonly used antibiotic for
bronchitis (48% of patients). For patients requiring a
switch to a different antibiotic, macrolides were the most
frequent choice. The overall costs per episode were $97
for pharyngitis, $114 for both OM and sinusitis, and
$133 for bronchitis. The proportion of total costs related
to follow-up treatment ranged from 19% for pharyngitis
to 32% for OM. Antibiotics accounted for 19% (for
pharyngitis) to 29% (for sinusitis) of overall costs. CON-
CLUSIONS: The costs of treatment episodes for RTIs are
fairly substantial and vary by condition. While the initial
encounter accounts for the majority of the costs, the ex-
penses associated with the need for additional treatment
are important to consider.
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COST COMPARISON OF GATIFLOXACIN 
VERSUS LEVOFLOXACIN IN THE TREATMENT 
OF COMMUNITY-ACQUIRED PNEUMONIA IN 
AN OUTPATIENT POPULATION
Bell TJ1, Loomis BR1, Mauskopf JA1, L’Italien GJ2,
Gallagher KM2
1RTI, Research Triangle Park, NC, USA; 2Bristol-Myers Squibb, 
Wallingford, CT, USA
OBJECTIVE: In addition to information about efficacy
and safety, decision-makers are interested in information
about the impact of new drug treatments on health care
costs. The objective is to determine the impact of using
gatifloxacin versus levofloxacin on total costs among
outpatient adults with community-acquired pneumonia
(CAP). METHODS: Patients were randomized to receive
either gatifloxacin (GAT) or levofloxacin (LEV) once
daily. Data were collected on efficacy, safety, and medi-
cal care resource use from 163 GAT and 176 LEV clini-
cally evaluable patients. Medical care resource use infor-
mation included the dose and duration of the study and
concomitant medications, duration of intensive care unit
(ICU) and non-ICU hospital stay, and number of outpa-
tient physician visits. We used a multivariate regression
analysis to determine the impact of treatment on total
costs. The dependent variable was the logarithm of total
costs to adjust for the left skewness found in the cost
data. The regression analysis controlled for disease sever-
ity, admission to the hospital on the day of (or before)
randomization, and prognostic factors (including age,
presence of comorbidities, and a previous CAP episode
within the last 12 months). RESULTS: GAT achieved a
cure rate of 96% compared to 94% for LEV. Based on
results from the multivariate regression analysis, patients
in the GAT arm could expect total costs that were ap-
proximately 8% lower (on average) than the total costs
incurred by patients in the LEV arm. Patients admitted to
the hospital on the day of (or before) randomization
could expect total costs that were nearly 51 times higher.
Hospital admission on the day of (or before) randomiza-
tion was the only statistically significant driver of ex-
pected total cost. CONCLUSION: GAT shows a trend to
be less costly and have a higher cure rate than LEV for
outpatients with CAP.
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ECONOMIC EVALUATION OF MACROLIDES 
AND FLUOROQUINOLONES FOR THE 
TREATMENT OF RESPIRATORY TRACT 
INFECTIONS
Lachaine J1, Laurier C1, Manzi P2
1University of Montreal, Montreal, QC, Canada; 2Abbott 
Laboratories Ltd, St-Laurent, QC, Canada
BACKGROUND: In the field of respiratory tract infec-
tions (RTI), concern about the efficiency of various treat-
ments has increased with the introduction of newer anti-
biotics often associated with higher acquisition costs.
These include second-generation macrolides and fluoro-
quinolones, which constitute alternative strategies to
amoxicillin and erythromycin. OBJECTIVES: To evalu-
ate, from a cost-efficacy standpoint, how these newer
agents compare with each other in the treatment of com-
munity acquired RTI in adults. METHODS: Cost-effi-
cacy analyses were done using decision-analysis tech-
niques based on efficacy and safety data of published
clinical trials. The analyses were performed from the per-
spective of a provincial third-party payer. Costs consid-
ered were those of antibiotics, physicians and pharma-
cists services and diagnostic procedures. RTI for which
analyses were performed are: bronchitis, community ac-
quired pneumonia, otitis media, pharyngitis and sinusitis.
Specific antibiotics compared were: azithromycin, cipro-
floxacin, clarithromycin, grepafloxacin, levofloxacin and
ofloxacin. RESULTS: Following a review of the literature
using Medline and Current Contents, 98 articles pub-
lished between January 1986 and December 1999 met
the inclusion criteria and provided efficacy and safety
data for the analyses. Efficacy rates for each antibiotic
did not differ strikingly and various dosages did not nec-
essarily have an impact on efficacy rates. Cost-efficacy
analyses indicate that, among the antibiotics studied, the
lowest cost-efficacy ratios were associated with either
azithromycin or clarithromycin at a dose of 250mg twice
daily. Azithromycin represented the preferred strategy for
the ambulatory treatment of community-acquired pneu-
monia and otitis media, while clarithromycin at a dose of
